DEEP RESEARCH · FDMT
4D Molecular Therapeutics: R100 벡터와 4D-150 중심의 바이오텍 분석
습성 황반변성 유전자 치료제 4D-150, 현금 런웨이, 플랫폼 해자를 중심으로 본다.
투자 판단의 책임은 본인에게 있습니다. 본 자료는 리서치이며 매수·매도 추천이 아닙니다.
0. 결론 먼저
제 결론은 FDMT의 투자 논지가 4D-150 하나로 압축된다는 것입니다. 2027년 하반기 3상 52주 데이터라는 명확한 촉매가 있고, 2024년 말 현금 및 유가증권 5억 600만 달러와 2025년 Otsuka 계약금 8,500만 달러 및 5,000만 달러 이상의 R&D 비용 분담으로 2028년까지의 현금 런웨이를 확보했습니다.
공식 사실: 원문은 4DMT PRISM Phase 2 데이터, 파이프라인 집중 발표, Otsuka 라이선스 계약을 주요 근거로 사용했습니다.
FDMT 투자 논지플랫폼, 임상, 재무 런웨이의 결합
R100 벡터IVT 투여와 저용량 고효율
4D-150습성 AMD/DME 핵심 자산
현금2024년 말 $506M, Otsuka upfront $85M
촉매2027년 하반기 3상 52주 데이터
FDMT는 자금 조달 압박보다 임상 성공 여부가 핵심 변수인 구조로 바뀌었다.
1. 회사와 비즈니스 모델
4D Molecular Therapeutics는 임상 단계 유전자 치료제 기업입니다. 핵심은 자연형 AAV가 아니라 약 10억 개 합성 캡시드 라이브러리에서 표적 조직에 맞는 벡터를 선별하는 Therapeutic Vector Evolution 플랫폼입니다. 내부 파이프라인은 안과, 폐, 심장을 중심으로 하고, 플랫폼 및 벡터 기술은 Roche, Pfizer, Astellas, Otsuka 등과의 협업 및 라이선싱으로 외부 검증을 받았습니다.
내부 개발
4D-150
습성 AMD와 DME를 겨냥한 핵심 자산입니다. 기존 반복 주사 치료를 단 한 번의 IVT 주사로 대체하는 Backbone Therapy를 목표로 합니다.
플랫폼
R100/A101
R100은 안과, A101은 폐 질환 쪽에서 플랫폼 가치를 보여주는 벡터로 정리됩니다.
라이선스
빅파마 검증
Astellas R100 계약은 upfront $20M, 총 $942.5M 규모였고, Otsuka APAC 계약은 upfront $85M, R&D 분담 $50M+, 총 $471M+ 규모로 제시되었습니다.
2. 재무 런웨이
| 항목 | 2024 | 2023 | 2022 |
|---|---|---|---|
| 수익 | $37K | $20.723M | $3.129M |
| R&D 비용 | $(187.841)M | $(97.096)M | $(80.253)M |
| 순손실 | $(160.868)M | N/A | N/A |
| 기말 현금 및 유가증권 | $506M | N/A | $299M |
해석: FDMT의 영업현금흐름은 전형적인 임상 바이오텍처럼 R&D 지출 때문에 마이너스입니다. 그러나 2024년 2월 약 $300M 공모, 2025년 10월 Otsuka 계약, R&D 비용 분담 덕분에 2027년 하반기 데이터 발표와 2028년 BLA 준비까지 버틸 수 있는 시간 자산을 확보했습니다.
3. 4D-150 경쟁 구도
| 후보물질 | 회사 | 투여 경로 | 효능 | 핵심 리스크/강점 |
|---|---|---|---|---|
| 4D-150 | 4DMT | IVT, 외래 진료실 | 주사 89% 감소, 77% 환자 24주 추가 주사 불필요 | 3상 용량에서 유의미한 염증 없음 |
| ABBV-RGX-314 | REGENXBIO/AbbVie | 망막하 수술 | 주사 97% 감소(P2 기준) | 효능은 우수하나 수술실과 전문 수술 부담 |
| Ixo-vec | Adverum | IVT | 장기 효능 유지 | DME 임상에서 심각한 염증과 실명 사례로 개발 중단 |
해석: 원문은 4D-150을 효능, 안전성, 편의성의 골디락스 포지션으로 봅니다. IVT 투여는 기존 안과 진료실 프로세스와 맞아 상업 침투율이 높을 수 있고, 낮은 용량의 R100 벡터가 Adverum의 염증 문제와 차별화되는 지점입니다.
4. 연혁과 촉매
- 2013년: David Kirn과 David Schaffer가 UC Berkeley 기술 기반으로 공동 창업.
- 2020년 6월: Series C $75M, Viking Global 주도.
- 2020년 12월: 나스닥 IPO, 주당 $23.00, 약 $222M 조달.
- 2023년 7월: Astellas에 R100 벡터 기술 라이선스.
- 2024년 2월: 주당 $29.50, 약 $300M 공모 증자로 3상 자금 확보.
- 2025년 1월: 4D-150과 4D-710 중심으로 파이프라인 집중.
- 2025년 10월: Otsuka와 APAC 독점 라이선스 계약.
- 2027년 하반기: 4FRONT-1/2 52주 데이터 발표 예정.
5. 최종 평가
FDMT는 일반적인 플랫폼 바이오텍보다 훨씬 이벤트 중심적입니다. 4D-150이 성공하면 안과 시장에서 큰 상업적 옵션이 열리고, 4D-710은 장기 콜옵션이 됩니다. 실패하면 플랫폼 신뢰도와 현금 가치 모두 급격히 재평가될 수 있습니다. 따라서 제 판단의 핵심은 2027년 데이터 전까지 현금이 충분하다는 점과, 임상 차별화가 안전성과 편의성에서 나온다는 점입니다.
출처
- Original post: https://m.blog.naver.com/PostView.naver?blogId=star_of_self&logNo=224069494792
- Reference 1: https://ir.4dmoleculartherapeutics.com/static-files/eadb0060-4b5c-475a-a95d-dd474e535270
- Reference 2: https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-announces-positive-phase-2-prism-interim-results
- Reference 3: https://www.pharmavoice.com/news/gene-therapy-amd-4d-molecular-abbvie-regenxbio/727942/
- Reference 4: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-focuses-pipeline-prioritize-4d-150-wet-amd-dme-and-4d-710/
- Reference 5: https://www.stocktitan.net/news/FDMT/4dmt-announces-exclusive-license-agreement-with-otsuka-zfr98g53z11c.html
- Reference 6: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-pricing-upsized-public-0
- Reference 7: https://www.sec.gov/Archives/edgar/data/1650648/000095017025106244/fdmt-20250630.htm
- Reference 8: https://d18rn0p25nwr6d.cloudfront.net/CIK-0001501756/612be6be-e5c8-41c0-a9af-b33b5f0c870b.xls
- Reference 9: https://ir.4dmoleculartherapeutics.com/static-files/98d9a295-b2af-4df2-897d-68ca354503e2
- Reference 10: https://4dmoleculartherapeutics.com/technology/
- Reference 11: https://ir.4dmoleculartherapeutics.com/
- Reference 12: https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Gene-Tx-for-Ophthalmic-Disorders-Summit-2023_4D-175_Calton_FINAL.pdf
- Reference 13: https://4dmoleculartherapeutics.com/
- Reference 14: https://4dmoleculartherapeutics.com/pipeline/
- Reference 15: https://dcfmodeling.com/blogs/history/fdmt-history-mission-ownership#:~:text=It%20Makes%20Money-,4D%20Molecular%20Therapeutics%2C%20Inc.,innovative%20gene%20therapy%20product%20candidates.
- Reference 16: https://ir.4dmoleculartherapeutics.com/node/6731/html
- Reference 17: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-corporate-webcast-review-interim-52-week-results/
- Reference 18: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-presents-positive-data-phase-ii-study-subretinal-abbv
- Reference 19: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-long-term-data-phase-12-prism-clinical
- Reference 20: https://www.pfizer.com/news/press-release/press-release-detail/4d-molecular-therapeutics-announces-collaboration-pfizer
- Reference 21: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/astellas-and-4d-molecular-therapeutics-4dmt-enter-license
- Reference 22: https://www.stifel.wallst.com/research/company/companyNews.asp?symbol=FDMT&docKey=100-303u2432-1
- Reference 23: https://4dmt.gcs-web.com/sec-filings
- Reference 24: https://ir.4dmoleculartherapeutics.com/node/9626/html
- Reference 25: https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-reports-full-year-2024-financial-results-operational/
- Reference 26: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-reports-full-year-2023-financial-results-and-operational
- Reference 27: https://ir.4dmoleculartherapeutics.com/static-files/a9b2e3e9-a8bb-422b-8e0a-b749edb7362b
- Reference 28: https://4dmt.gcs-web.com/node/9616/html
- Reference 29: https://ir.4dmoleculartherapeutics.com/node/8501/html
- Reference 30: https://4dmt.gcs-web.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-pricing-public-offering
- Reference 31: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-closing-initial-public
- Reference 32: https://ir.4dmoleculartherapeutics.com/static-files/4c03dbc3-afad-481d-b071-79a3d1103558
- Reference 33: https://www.cellandgene.com/doc/an-analysis-of-the-gene-therapy-viral-vector-landscape-0001
- Reference 34: https://www.prnewswire.com/news-releases/astellas-and-4d-molecular-therapeutics-4dmt-enter-into-license-agreement-to-use-4dmts-proprietary-intravitreal-r100-vector-for-rare-ophthalmic-targets-301872750.html
- Reference 35: https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-announces-landmark-publication-4d-150-preclinical-data/
- Reference 36: https://www.tandfonline.com/doi/full/10.1080/17469899.2022.2147927
- Reference 37: https://www.fiercebiotech.com/biotech/adverums-gene-therapy-shows-promise-wet-amd-ph-2-though-questions-remain
- Reference 38: https://pmc.ncbi.nlm.nih.gov/articles/PMC10789843/
- Reference 39: https://www.retinalphysician.com/issues/2024/april/gene-therapy-for-wet-age-related-macular-degeneration/
- Reference 40: https://dcfmodeling.com/blogs/history/fdmt-history-mission-ownership
- Reference 41: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-focuses-pipeline-prioritize-4d-150-wet-amd-dme-and-4d-710
- Reference 42: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-advances-4d-710-phase-2-additional-funding-and-support
- Reference 43: https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-participate-chardans-9th-annual-genetic-medicines
- Reference 44: https://www.clinicaltrialvanguard.com/news/4dmts-cf-drug-advances-to-phase-2-with-foundation-support/
- Reference 45: https://vcresearch.berkeley.edu/faculty/david-schaffer
- Reference 46: https://finviz.com/quote.ashx?t=FDMT
- Reference 47: https://www.sec.gov/Archives/edgar/data/1650648/000095017022004794/fdmt-20211231.htm
- Reference 48: https://4dmt.gcs-web.com/news-releases/news-release-details/4d-molecular-therapeutics-raises-75-million-series-c-financing
- Reference 49: https://forgeglobal.com/4d-molecular-therapeutics-4dmt_ipo/
- Reference 50: https://ir.4dmoleculartherapeutics.com/node/6576/html
- Reference 51: https://ir.4dmoleculartherapeutics.com/press-releases?mobile=1&page=5
- Reference 52: https://www.globenewswire.com/news-release/2025/01/10/3007636/0/en/4DMT-Focuses-Pipeline-to-Prioritize-4D-150-in-Wet-AMD-DME-and-4D-710-in-CF-and-Extends-Cash-Runway.html
- Reference 53: https://ois.net/david-kirn/
- Reference 54: https://en.wikipedia.org/wiki/David_H._Kirn
- Reference 55: https://pmwcintl.com/speaker/david-kirn-381_4dmt_2024sv/
- Reference 56: https://schafferlab.berkeley.edu/people/david-v-schaffer/
- Reference 57: https://ir.4dmoleculartherapeutics.com/press-releases?mobile=1&page=10
- Reference 58: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-resignation-professor-david/
- Reference 59: https://ir.4dmoleculartherapeutics.com/static-files/cae39840-af82-4a91-b899-1a77831141cd
- Reference 60: https://www.biospace.com/press-releases/4dmt-announces-leadership-expansion-with-proven-late-stage-executives-to-drive-4d-150-execution-and-bla-readiness
- Reference 61: https://www.biospace.com/press-releases/4dmt-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants
- Reference 62: https://www.stocktitan.net/news/FDMT/4dmt-announces-pricing-of-100-million-offering-of-common-stock-and-gpdi5rq84qkr.html
- Reference 63: https://www.nasdaq.com/market-activity/stocks/fdmt/institutional-holdings
- Reference 64: https://www.secform4.com/insider-holders/1650648.html
- Reference 65: https://fintel.io/so/us/fdmt
- Reference 66: https://www.racap.com/
- Reference 67: https://www.bedrockgroup.com/exploring-the-biotechnology-sector-with-ra-capital-management/
- Reference 68: https://www.racap.com/faq
- Reference 69: https://massinvestordatabase.com/Biotechnology+Value+Fund/investmentfirm.php
- Reference 70: https://capitalaum.com/hedge-funds/bvfpartners-sanfrancisco-ca.htm
- Reference 71: https://regents.umich.edu/files/meetings/12-21/2021-12-IX-5.pdf
- Reference 72: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and/
- Reference 73: https://pmc.ncbi.nlm.nih.gov/articles/PMC11614000/
- Reference 74: https://www.retina-specialist.com/article/update-gene-therapy-clinical-trials-in-neovascular-agerelated-macular-degeneration
- Reference 75: https://investors.adverum.com/press_releases/news-details/2023/Adverum-Biotechnologies-Announces-3-Year-Efficacy-and-Safety-Resultsfrom-the-OPTIC-Extension-Study-in-Patients-with-Wet-AMD-at-AAO-2023/default.aspx
- Reference 76: https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-reports-first-quarter-2025-financial-results-operational
- Reference 77: https://legaldesire.com/latham-watkins-advises-4d-molecular-therapeutics-on-us100-million-offering-of-common-stock-and-pre-funded-warrants/
- Reference 78: https://www.sec.gov/Archives/edgar/data/1299130/000129913021000135/pacb-20210616xdef14a.htm
- Reference 79: https://www.sec.gov/Archives/edgar/data/1650648/000095017025067040/fdmt-20250331.htm
- Reference 80: https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances
- Reference 81: https://www.hklaw.com/en/insights/publications/2025/10/whats-new-in-fdas-latest-cell-and-gene-therapy-guidance
- Reference 82: https://en.hdbuzz.net/uniqure-and-fda-no-longer-in-alignment-on-approval-pathway-for-amt-130/
- Reference 83: https://www.healthadvances.com/insights/blog/2025-marks-technology-regulatory-and-disease-area-shifts-in-cell-and-gene-therapy
- Reference 84: https://itif.org/publications/2025/02/25/the-inflation-reduction-act-is-negotiating-the-united-states-out-of-drug-innovation/
- Reference 85: https://goodlifesci.sidley.com/2023/05/23/impact-of-inflation-reduction-act-on-drug-development-for-u-s-market/
- Reference 86: https://www.grandviewresearch.com/industry-analysis/gene-therapy-market
- Reference 87: https://www.towardshealthcare.com/insights/cell-and-gene-therapy-market